Publication Title
Saudi Pharm J
Document Type
Article
Publication Date
4-1-2020
Keywords
ADME; ADME-Absorption, Distribution, Metabolism, and Excretion; AO/EtBr, Acridine orange/ethidium bromide; Apoptosis; Docking; EGFR; EGFR, Epidermal Growth Factor Receptor; ER, Estrogen Receptor; FACS, Fluorescence-activated cell sorting; FITC, Fluorescein isothiocyanate; Gene expression; IC50, The half maximal inhibitory concentration; MCF-7, Michigan Cancer Foundation-7; PI3K, Phosphoinositide 3-kinase; PR, Progesterone Receptor; QSAR; QSAR, Quantitative structure activity relationship; RTPCR, Reverse Transcriptase PCR; SkBr3, Sloan–Kettering Cancer Center; THMPP, 2-((1, 2, 3, 4-Tetrahydroquinolin-1-yl) (4 methoxyphenyl) methyl) phenol; Tetrahydroquinoline
Abstract
Breast cancer is the most common cancer that majorly affects female. The present study is focused on exploring the potential anticancer activity of 2-((1, 2, 3, 4-Tetrahydroquinolin-1-yl) (4 methoxyphenyl) methyl) phenol (THMPP), against human breast cancer. The mechanism of action, activation of specific signaling pathways, structural activity relationship and drug-likeness properties of THMPP remains elusive. Cell proliferation and viability assay, caspase enzyme activity, DNA fragmentation and FITC/Annexin V, AO/EtBr staining, RT-PCR, QSAR and ADME analysis were executed to understand the mode of action of the drug. The effect of THMPP on multiple breast cancer cell lines (MCF-7 and SkBr3), and non-tumorigenic cell line (H9C2) was assessed by MTT assay. THMPP at IC
Clinical Institute
Cancer
Clinical Institute
Women & Children
Specialty
Oncology
